Daniel N. Swisher, Jr
2012 - Sunesis Pharmaceuticals
In 2012, Daniel N. Swisher, Jr earned a total compensation of $1.2M as CEO and President at Sunesis Pharmaceuticals, a 31% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $217,000 |
|---|---|
| Option Awards | $522,198 |
| Salary | $431,894 |
| Other | $3,130 |
| Total | $1,174,222 |
Swisher received $522.2K in option awards, accounting for 44% of the total pay in 2012.
Swisher also received $217K in non-equity incentive plan, $431.9K in salary and $3.1K in other compensation.
Rankings
In 2012, Daniel N. Swisher, Jr's compensation ranked 5,507th out of 11,487 executives tracked by ExecPay. In other words, Swisher earned more than 52.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,507 out of 11,487 | 52nd |
Division Manufacturing | 1,941 out of 4,253 | 54th |
Major group Chemicals And Allied Products | 469 out of 1,198 | 61st |
Industry group Drugs | 311 out of 920 | 66th |
Industry Pharmaceutical Preparations | 242 out of 700 | 65th |
Source: SEC filing on April 25, 2013.
Swisher's colleagues
We found three more compensation records of executives who worked with Daniel N. Swisher, Jr at Sunesis Pharmaceuticals in 2012.
News
Jazz Pharmaceuticals CEO Bruce Cozadd's 2021 pay jumps 25% to $16M
June 10, 2022
Jazz Pharmaceuticals CEO Bruce Cozadd's 2020 pay slips 15% to $13M
June 11, 2021
Jazz Pharmaceuticals CEO Bruce Cozadd's 2019 pay jumps 29% to $15M
June 12, 2020
Jazz Pharmaceuticals CEO Bruce Cozadd's 2018 pay rises 11% to $11M
June 14, 2019